Market Overview:
The global central nervous system drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of neurological disorders, rising geriatric population, and growing demand for CNS drugs in emerging markets. By type, the global central nervous system drugs market is segmented into over-the-counter (OTC) and prescription (Rx) drugs. The Rx drug segment is expected to grow at a higher CAGR than the OTC drug segment during the forecast period. This growth can be attributed to factors such as increasing prevalence of neurological disorders and growing demand for CNS therapies among patients with chronic diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. By application, the global central nervous system drugs market is divided into hospital pharmacies and retail pharmacies. The hospital pharmacy segment dominates this market owing to high spending on medications by hospitals compared with retail pharmacies due to increased patient admissions for various neurological conditions including stroke, epilepsy seizure disorder etc.
Product Definition:
Central nervous system drugs are a type of drug that is used to treat disorders or diseases that affect the central nervous system. This type of drug can include medications such as antidepressants, antiepileptic drugs, and neuroleptics. Central nervous system drugs are important because they can help to improve the quality of life for people who suffer from diseases or disorders that affect the central nervous system.
OTC:
OTC stands for Over-the-Counter and is a category of pharmaceutical drugs that are sold without a prescription. OTC drugs can be used by individuals of any age, but they were initially intended for use by consumers who were not well educated or experienced in the medical field and/or had no access to healthcare providers.
Rx Drugs:
Rx drugs are the ones purchased by patients from a pharmacy or drug store. They are used to treat a particular disease, disorder or condition and hence have become an indispensable part of medical science. The global central nervous system drugs market is expected to grow at a lucrative rate during the forecast period owing to increasing incidences of neurological disorders such as Alzheimer’s, Parkinson’s disease, Epilepsy and others.
Application Insights:
The hospital application segment held the largest share of 64.1% in 2017 owing to the high usage of CNS drugs for treating various neurological disorders in hospitals. The increasing prevalence of neurological diseases, such as Parkinson¢â‚¬â„¢s disease, Alzheimer¢â‚¬â„¢s disease, Hunter¢â‚¬œ Hayes syndrome and brain tumor causes is expected to drive the demand for central nervous system drugs at a global level during the forecast period.
In addition, an increase in healthcare expenditure due to growing aging population across all regions coupled with rising incidences of drug-resistant epilepsy is anticipated to boost overall spending on healthcare which subsequently will fuel demand for CNS medicines over the forecast period.
Regional Analysis:
North America dominated the global CNS drugs market in 2017. The presence of key players, favorable reimbursement scenario, and high healthcare expenditure are some of the factors responsible for its large share. In addition, increasing prevalence of neurological disorders is also expected to drive growth during the forecast period. For instance, as per a recent study published in JAMA Neurology, approximately 60 million people in North America were suffering from neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson's disease (PD).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income leading to an increase in demand for medicines among patients; growing awareness about treatment options; improving healthcare facilities; and availability of effective treatment methods for CNS diseases.
Growth Factors:
- Increasing incidence of neurological disorders: The global prevalence of neurological disorders is increasing at a significant rate. This is primarily attributed to the changing lifestyle and environmental factors. This, in turn, is expected to drive the demand for CNS drugs in the coming years.
- Growing awareness about CNS drugs: There is a growing awareness among people about Central Nervous System (CNS) drugs and their benefits. This is helping to boost the demand for these drugs across the globe.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are investing heavily in research and development activities to develop new and innovative CNS drugs products that can address various unmet needs of patients suffering from neurological disorders .This is expected to fuel the growth of this market in the coming years .
- . Technological advancements :The Central Nervous System Drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Central Nervous System Drugs Market Research Report
By Type
OTC, Rx Drugs
By Application
Hospital, Retail Pharmacy
By Companies
Biogen, Pfizer, Teva, Novartis, Johnson & Johnson, EliLilly, Otsuka, Merck, AstraZeneca, Novartis, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global Central Nervous System Drugs Market Report Segments:
The global Central Nervous System Drugs market is segmented on the basis of:
Types
OTC, Rx Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Pfizer
- Teva
- Novartis
- Johnson & Johnson
- EliLilly
- Otsuka
- Merck
- AstraZeneca
- Novartis
- Biogen
Highlights of The Central Nervous System Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OTC
- Rx Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Central Nervous System Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Central nervous system drugs are medications that are used to treat conditions that affect the brain and spinal cord. These conditions can include Alzheimer's disease, stroke, multiple sclerosis, and epilepsy.
Some of the major companies in the central nervous system drugs market are Biogen, Pfizer, Teva, Novartis, Johnson & Johnson, EliLilly, Otsuka, Merck, AstraZeneca, Novartis, Biogen.
The central nervous system drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Central Nervous System Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Central Nervous System Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Central Nervous System Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Central Nervous System Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Central Nervous System Drugs Market Size & Forecast, 2020-2028
4.5.1 Central Nervous System Drugs Market Size and Y-o-Y Growth
4.5.2 Central Nervous System Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OTC
5.2.2 Rx Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Central Nervous System Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Central Nervous System Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OTC
9.6.2 Rx Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OTC
10.6.2 Rx Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OTC
11.6.2 Rx Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OTC
12.6.2 Rx Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OTC
13.6.2 Rx Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Central Nervous System Drugs Market: Competitive Dashboard
14.2 Global Central Nervous System Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Pfizer
14.3.3 Teva
14.3.4 Novartis
14.3.5 Johnson & Johnson
14.3.6 EliLilly
14.3.7 Otsuka
14.3.8 Merck
14.3.9 AstraZeneca
14.3.10 Novartis
14.3.11 Biogen
